Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Nat Rev Nephrol. 2019 May;15(5):275–289. doi: 10.1038/s41581-019-0119-6

Fig. 5 ∣. Dextran-sulfate apheresis enables prolongation of pregnancy in women with pre-eclampsia.

Fig. 5 ∣

Pretreatment soluble fms-like tyrosine kinase 1 (sFLT1):placental growth factor (PlGF) ratios and pregnancy prolongation in women with pre-eclampsia who were treated with apheresis and untreated contemporaneous controls. Pregnancy continued for 8 days (range 2–11) and 15 days (range 11–21) in women treated once (n = 6) and multiple times (n = 5), respectively, compared with 3 days (range 0–14) in untreated contemporaneous women with pre-eclampsia (n = 22). Republished with permission of American Society of Nephrology, from Thadani et al., Removal of soluble fms-like tyrosine kinase 1 by dextran sulfate apheresis in preeclampsia. Journal of the American Society of Nephrology 27 (2016) (REF.204).